320 related articles for article (PubMed ID: 33689087)
1. Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines.
Yi JS; Perla S; Huang Y; Mizuno K; Giordano FJ; Vinks AA; Bennett AM
Cardiovasc Drugs Ther; 2022 Aug; 36(4):589-604. PubMed ID: 33689087
[TBL] [Abstract][Full Text] [Related]
2. Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines.
Yi JS; Perla S; Enyenihi L; Bennett AM
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32584792
[TBL] [Abstract][Full Text] [Related]
3. In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.
Wang J; Chandrasekhar V; Abbadessa G; Yu Y; Schwartz B; Kontaridis MI
PLoS One; 2017; 12(6):e0178905. PubMed ID: 28582432
[TBL] [Abstract][Full Text] [Related]
4. Low-dose dasatinib rescues cardiac function in Noonan syndrome.
Yi JS; Huang Y; Kwaczala AT; Kuo IY; Ehrlich BE; Campbell SG; Giordano FJ; Bennett AM
JCI Insight; 2016 Dec; 1(20):e90220. PubMed ID: 27942593
[TBL] [Abstract][Full Text] [Related]
5. Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines.
Roy R; Krenz M
J Mol Cell Cardiol; 2017 Nov; 112():83-90. PubMed ID: 28911943
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.
Marin TM; Keith K; Davies B; Conner DA; Guha P; Kalaitzidis D; Wu X; Lauriol J; Wang B; Bauer M; Bronson R; Franchini KG; Neel BG; Kontaridis MI
J Clin Invest; 2011 Mar; 121(3):1026-43. PubMed ID: 21339643
[TBL] [Abstract][Full Text] [Related]
7. Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog.
Hahn A; Lauriol J; Thul J; Behnke-Hall K; Logeswaran T; Schänzer A; Böğürcü N; Garvalov BK; Zenker M; Gelb BD; von Gerlach S; Kandolf R; Kontaridis MI; Schranz D
Am J Med Genet A; 2015 Apr; 167A(4):744-51. PubMed ID: 25708222
[TBL] [Abstract][Full Text] [Related]
8. Genotype-phenotype association by echocardiography offers incremental value in patients with Noonan Syndrome with Multiple Lentigines.
Kauffman H; Ahrens-Nicklas RC; Calderon-Anyosa RJC; Ritter AL; Lin KY; Rossano JW; Quartermain MD; Banerjee A
Pediatr Res; 2021 Aug; 90(2):444-451. PubMed ID: 33318624
[TBL] [Abstract][Full Text] [Related]
9. Case report: Distinctive cardiac features and phenotypic characteristics of Noonan syndrome with multiple lentigines among three generations in one family.
Chan CH; Chu MF; Lam UP; Mok TM; Tam WC; Tomlinson B; Coelho R; Évora M
Front Cardiovasc Med; 2023; 10():1225667. PubMed ID: 37692036
[TBL] [Abstract][Full Text] [Related]
10. Elevated Ca2+ transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan syndrome with multiple lentigines.
Clay SA; Domeier TL; Hanft LM; McDonald KS; Krenz M
Am J Physiol Heart Circ Physiol; 2015 May; 308(9):H1086-95. PubMed ID: 25724491
[TBL] [Abstract][Full Text] [Related]
11. Familial aggregation of genetically heterogeneous hypertrophic cardiomyopathy: a boy with LEOPARD syndrome due to PTPN11 mutation and his nonsyndromic father lacking PTPN11 mutations.
Digilio MC; Pacileo G; Sarkozy A; Limongelli G; Conti E; Cerrato F; Marino B; Pizzuti A; Calabrò R; Dallapiccola B
Birth Defects Res A Clin Mol Teratol; 2004 Feb; 70(2):95-8. PubMed ID: 14991917
[TBL] [Abstract][Full Text] [Related]
12. Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.
Lauriol J; Cabrera JR; Roy A; Keith K; Hough SM; Damilano F; Wang B; Segarra GC; Flessa ME; Miller LE; Das S; Bronson R; Lee KH; Kontaridis MI
J Clin Invest; 2016 Aug; 126(8):2989-3005. PubMed ID: 27348588
[TBL] [Abstract][Full Text] [Related]
13. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
Schramm C; Fine DM; Edwards MA; Reeb AN; Krenz M
Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H231-43. PubMed ID: 22058153
[TBL] [Abstract][Full Text] [Related]
14. Generation of an induced pluripotent stem cell line (TRNDi003-A) from a Noonan syndrome with multiple lentigines (NSML) patient carrying a p.Q510P mutation in the PTPN11 gene.
Li R; Baskfield A; Lin Y; Beers J; Zou J; Liu C; Jaffré F; Roberts AE; Ottinger EA; Kontaridis MI; Zheng W
Stem Cell Res; 2019 Jan; 34():101374. PubMed ID: 30640061
[TBL] [Abstract][Full Text] [Related]
15. A novel heterozygous MAP2K1 mutation in a patient with Noonan syndrome with multiple lentigines.
Nishi E; Mizuno S; Nanjo Y; Niihori T; Fukushima Y; Matsubara Y; Aoki Y; Kosho T
Am J Med Genet A; 2015 Feb; 167A(2):407-11. PubMed ID: 25423878
[TBL] [Abstract][Full Text] [Related]
16. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
[TBL] [Abstract][Full Text] [Related]
17. Compound heterozygosity for PTPN11 variants in a subject with Noonan syndrome provides insights into the mechanism of SHP2-related disorders.
Lorca R; Pannone L; Cuesta-Llavona E; Bocchinfuso G; Rodríguez-Reguero J; Carpentieri G; Hernando I; Flex E; Tartaglia M; Coto E; Gómez J; Martinelli S
Clin Genet; 2021 Mar; 99(3):457-461. PubMed ID: 33354767
[TBL] [Abstract][Full Text] [Related]
18. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
Pandit B; Sarkozy A; Pennacchio LA; Carta C; Oishi K; Martinelli S; Pogna EA; Schackwitz W; Ustaszewska A; Landstrom A; Bos JM; Ommen SR; Esposito G; Lepri F; Faul C; Mundel P; López Siguero JP; Tenconi R; Selicorni A; Rossi C; Mazzanti L; Torrente I; Marino B; Digilio MC; Zampino G; Ackerman MJ; Dallapiccola B; Tartaglia M; Gelb BD
Nat Genet; 2007 Aug; 39(8):1007-12. PubMed ID: 17603483
[TBL] [Abstract][Full Text] [Related]
19. Investigating the reason for loss-of-function of Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) caused by Y279C mutation through molecular dynamics simulation.
Liu WS; Wang RR; Li WY; Rong M; Liu CL; Ma Y; Wang RL
J Biomol Struct Dyn; 2020 Jun; 38(9):2509-2520. PubMed ID: 31258001
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]